Kodiak Sciences (NASDAQ:KOD) Given New $5.00 Price Target at HC Wainwright

Kodiak Sciences (NASDAQ:KOD) had its price objective raised by HC Wainwright from $3.00 to $5.00 in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a neutral rating on the stock. HC Wainwright also issued estimates for Kodiak Sciences’ Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($4.21) EPS, FY2026 earnings at ($4.45) EPS, FY2027 earnings at ($4.40) EPS, FY2028 earnings at ($3.42) EPS and FY2029 earnings at ($1.87) EPS.

A number of other brokerages also recently issued reports on KOD. Barclays raised their price target on shares of Kodiak Sciences from $4.00 to $7.00 and gave the stock an “underweight” rating in a report on Thursday, August 14th. JPMorgan Chase & Co. upgraded shares of Kodiak Sciences from an “underweight” rating to a “neutral” rating and set a $15.00 price target for the company in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $11.75.

Kodiak Sciences Price Performance

Shares of NASDAQ KOD opened at $9.50 on Monday. The company has a 50 day simple moving average of $5.93 and a 200-day simple moving average of $4.51. The company has a market capitalization of $501.79 million, a P/E ratio of -2.50 and a beta of 2.41. Kodiak Sciences has a 1 year low of $1.92 and a 1 year high of $11.60.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.02). As a group, research analysts expect that Kodiak Sciences will post -3.45 EPS for the current year.

Hedge Funds Weigh In On Kodiak Sciences

A number of hedge funds have recently made changes to their positions in KOD. US Bancorp DE boosted its position in shares of Kodiak Sciences by 131.7% during the 1st quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after purchasing an additional 5,276 shares during the period. Vontobel Holding Ltd. purchased a new position in Kodiak Sciences in the 1st quarter valued at approximately $28,000. Headlands Technologies LLC boosted its position in Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after buying an additional 5,815 shares during the period. Walleye Capital LLC purchased a new position in Kodiak Sciences in the 1st quarter valued at approximately $49,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in Kodiak Sciences by 21.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company’s stock valued at $56,000 after buying an additional 2,691 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.